Xvivo Perfusion Ab Stock Performance
| XVIPF Stock | USD 24.15 1.34 5.26% |
On a scale of 0 to 100, Xvivo Perfusion holds a performance score of 11. The firm maintains a market beta of -0.37, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Xvivo Perfusion are expected to decrease at a much lower rate. During the bear market, Xvivo Perfusion is likely to outperform the market. Please check Xvivo Perfusion's treynor ratio, as well as the relationship between the semi variance and day median price , to make a quick decision on whether Xvivo Perfusion's historical returns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Xvivo Perfusion AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Xvivo Perfusion reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 354.2 M | |
| Total Cashflows From Investing Activities | -187.7 M |
Xvivo |
Xvivo Perfusion Relative Risk vs. Return Landscape
If you would invest 1,886 in Xvivo Perfusion AB on November 5, 2025 and sell it today you would earn a total of 529.00 from holding Xvivo Perfusion AB or generate 28.05% return on investment over 90 days. Xvivo Perfusion AB is currently producing 0.4484% returns and takes up 3.0072% volatility of returns over 90 trading days. Put another way, 27% of traded pink sheets are less volatile than Xvivo, and 91% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Xvivo Perfusion Target Price Odds to finish over Current Price
The tendency of Xvivo Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 24.15 | 90 days | 24.15 | roughly 2.59 |
Based on a normal probability distribution, the odds of Xvivo Perfusion to move above the current price in 90 days from now is roughly 2.59 (This Xvivo Perfusion AB probability density function shows the probability of Xvivo Pink Sheet to fall within a particular range of prices over 90 days) .
Xvivo Perfusion Price Density |
| Price |
Predictive Modules for Xvivo Perfusion
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Xvivo Perfusion AB. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Xvivo Perfusion Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Xvivo Perfusion is not an exception. The market had few large corrections towards the Xvivo Perfusion's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Xvivo Perfusion AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Xvivo Perfusion within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.59 | |
β | Beta against Dow Jones | -0.37 | |
σ | Overall volatility | 2.20 | |
Ir | Information ratio | 0.17 |
Xvivo Perfusion Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Xvivo Perfusion for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Xvivo Perfusion AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Xvivo Perfusion AB had very high historical volatility over the last 90 days | |
| Xvivo Perfusion AB has accumulated about 22.66 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 12.0% of the company outstanding shares are owned by insiders |
Xvivo Perfusion Fundamentals Growth
Xvivo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Xvivo Perfusion, and Xvivo Perfusion fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xvivo Pink Sheet performance.
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X | |||
| Revenue | 258.39 M | |||
| EBITDA | 39.2 M | |||
| Cash And Equivalents | 22.66 M | |||
| Cash Per Share | 0.86 X | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 2.28 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.10 X | |||
| Total Asset | 1.54 B | |||
About Xvivo Perfusion Performance
By analyzing Xvivo Perfusion's fundamental ratios, stakeholders can gain valuable insights into Xvivo Perfusion's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xvivo Perfusion has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xvivo Perfusion has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 115 people.Things to note about Xvivo Perfusion AB performance evaluation
Checking the ongoing alerts about Xvivo Perfusion for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Xvivo Perfusion AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xvivo Perfusion AB had very high historical volatility over the last 90 days | |
| Xvivo Perfusion AB has accumulated about 22.66 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 12.0% of the company outstanding shares are owned by insiders |
- Analyzing Xvivo Perfusion's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xvivo Perfusion's stock is overvalued or undervalued compared to its peers.
- Examining Xvivo Perfusion's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xvivo Perfusion's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xvivo Perfusion's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xvivo Perfusion's pink sheet. These opinions can provide insight into Xvivo Perfusion's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Xvivo Pink Sheet analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |